Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abuse-Deterrent Opioids Could Gain Significant First-Mover Advantage Under FDA Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA recommends head-to-head studies against already marketed products – an unusual development policy for the agency.

Advertisement

Related Content

Opioid Packaging Changes Might Deter Abuse – And Generic Competition
Final Generic Abuse-Deterrent Opioids Guidance Coming This Year
Final Generic Abuse-Deterrent Opioids Guidance Coming This Year
US FDA Might Face Funding Penalty For Missing User-Fee Goals
US FDA Might Face Funding Penalty For Missing User Fee Goals
Abuse-Deterrent Exemption From Medicaid Rebates Hinges On FDA Standards
Abuse-Deterrent Opioids: FDA Advocates Joint Brand-Generic Development Plan
Abuse-Deterrent Opioids: FDA Advocates Joint Brand-Generic Development Plan
Edoxaban Review ‘Not About Comparative Efficacy,’ FDA Says
FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel